Literature DB >> 29849216

Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?

Francesco Passiglia1, Luis E Raez2, Christian Rolfo3.   

Abstract

Entities:  

Year:  2018        PMID： 29849216      PMCID： PMC5949407          DOI： 10.21037/jtd.2018.03.92

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  28 in total

1.  Genotyping non-small cell lung cancer (NSCLC) in Latin America.

Authors:  Oscar Arrieta; Andrés Felipe Cardona; Guillermo Federico Bramuglia; Aly Gallo; Alma D Campos-Parra; Silvia Serrano; Marcelo Castro; Alejandro Avilés; Edgar Amorin; Ricardo Kirchuk; Mauricio Cuello; José Borbolla; Omar Riemersma; Henry Becerra; Rafael Rosell
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

2.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors:  Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Matthew Links; Val Gebski; Tony Mok; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-10-17       Impact factor: 15.609

5.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

7.  Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

Authors:  Ying Cheng; Haruyasu Murakami; Pan-Chyr Yang; Jianxing He; Kazuhiko Nakagawa; Jin Hyoung Kang; Joo-Hang Kim; Xin Wang; Sotaro Enatsu; Tarun Puri; Mauro Orlando; James Chih-Hsin Yang
Journal:  J Clin Oncol       Date:  2016-08-09       Impact factor: 44.544

8.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Authors:  Carlota Costa; Miguel Angel Molina; Ana Drozdowskyj; Ana Giménez-Capitán; Jordi Bertran-Alamillo; Niki Karachaliou; Radj Gervais; Bartomeu Massuti; Jia Wei; Teresa Moran; Margarita Majem; Enriqueta Felip; Enric Carcereny; Rosario Garcia-Campelo; Santiago Viteri; Miquel Taron; Mayumi Ono; Petros Giannikopoulos; Trever Bivona; Rafael Rosell
Journal:  Clin Cancer Res       Date:  2014-02-03       Impact factor: 12.531

10.  Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.

Authors:  Ken Uchibori; Naohiko Inase; Mitsugu Araki; Mayumi Kamada; Shigeo Sato; Yasushi Okuno; Naoya Fujita; Ryohei Katayama
Journal:  Nat Commun       Date:  2017-03-13       Impact factor: 14.919
View more
  3 in total

1.  AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.

Authors:  Donghwa Kim; Duc-Hiep Bach; Yan-Hua Fan; Thi-Thu-Trang Luu; Ji-Young Hong; Hyen Joo Park; Sang Kook Lee
Journal:  Cell Death Dis       Date:  2019-05-01       Impact factor: 8.469

Review 2.  Scar tissue to lung cancer; pathways and treatment.

Authors:  Konstantinos Sapalidis; Chrysanthi Sardeli; Efstathios Pavlidis; Georgios Koimtzis; Charilaos Koulouris; Nikolaos Michalopoulos; Stylianos Mantalovas; Theodora Tsiouda; Ioannis Passos; Christoforos Kosmidis; Dimitrios Giannakidis; Valeriu Surlin; Athanasios Katsaounis; Vyron Alexandrou; Aikaterini Amaniti; Paul Zarogoulidis; Haidong Huang; Qiang Li; Stelian Mogoanta; Isaac Kesisoglou
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

3.  Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.

Authors:  Nele Van Der Steen; Kaylee Keller; Henk Dekker; Letizia Porcelli; Richard J Honeywell; Johan Van Meerloo; René J P Musters; Ietje Kathmann; Adam E Frampton; Daniel S K Liu; Rob Ruijtenbeek; Christian Rolfo; Patrick Pauwels; Elisa Giovannetti; Godefridus J Peters
Journal:  J Cell Physiol       Date:  2020-01-20       Impact factor: 6.384
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.